Testing BL-M05D1 for advanced solid tumors with CLDN18.2
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, BL-M05D1, in people with advanced solid tumors that have a protein called CLDN18.2. The goal is to see if it's safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a solid tumor that has come back or spread after at least one prior treatment.
- Your tumor must have the CLDN18.2 protein, which will be checked on a sample from your tumor.
- You need to have at least one tumor that can be measured on scans.
- You must be in generally good health, able to take care of yourself (ECOG 0 or 1).
- You must not have serious heart, lung, or other major organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
This trial tests a new drug, BL-M09D1, for people with advanced or metastatic gastrointestinal or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is.
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
This trial tests a new drug called BL-M08D for people with advanced digestive tract tumors or other solid tumors that have spread. It aims to see if the drug can shrink tumors and improve survival, while monitoring safety.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.